Skip to main content
Safety & Side Effects

GLP-1 & Birth Control: What to Know

Updated October 20, 2026Safety & Side EffectsPublished by Surfbound Health

If you decide to start

Compounded semaglutide $169/month · tirzepatide $219/month

One flat price at every prescribed dose. No membership fee. Medication and discreet shipping included if prescribed.

Quick answer

Tirzepatide's labeling advises switching to a non-oral contraceptive or adding a barrier method for 4 weeks after starting and after each dose increase, because a single-dose study found lower oral-contraceptive exposure. The current Wegovy label reports no clinically significant change in exposure with semaglutide, so don't apply tirzepatide's rule automatically. Patches, rings, implants, injectables and IUDs do not rely on stomach absorption and are not expected to be affected. Discuss contraception and pregnancy plans with your prescriber.

A critical interaction that is not discussed enough

The US prescribing information for tirzepatide (Zepbound and Mounjaro) includes a specific instruction about oral contraceptive exposure. The semaglutide label is different: the current Wegovy label reports no clinically significant change in exposure to ethinyl estradiol or levonorgestrel. If you rely on oral birth control pills and are considering GLP-1 treatment, this is a conversation to have with your prescriber — ideally before starting the medication.

The mechanism: delayed gastric emptying and pill absorption

GLP-1 medications slow gastric emptying — food and medications stay in the stomach longer. For most medications this has little clinical significance. For oral contraceptives the concern is timing: if a pill stays in the stomach longer than usual, the timing and completeness of absorption may change, and altered absorption could in theory reduce contraceptive effectiveness.

Tirzepatide has a specific four-week backup/non-oral contraception instruction. The current Wegovy label reports no clinically significant change in exposure to ethinyl estradiol or levonorgestrel with semaglutide. Do not automatically apply tirzepatide’s interaction rule to semaglutide. Vomiting or diarrhea still requires advice specific to the contraceptive being used.

What the data actually shows

In a study using a single 5 mg tirzepatide dose with a combined oral contraceptive, peak concentrations of ethinyl estradiol, norgestimate and norelgestromin decreased by 59%, 66% and 55%, respectively. Total exposure decreased by 20%, 21% and 23%. These are drug-exposure measurements, not measured reductions in contraceptive effectiveness. The US label consequently advises a non-oral method or an added barrier method for 4 weeks after starting tirzepatide and after each dose increase.

Practical guidance by contraceptive method

  • Combined oral contraceptive pills: this is the main concern. The US tirzepatide label advises switching to a non-oral contraceptive or adding a barrier method, such as condoms, for 4 weeks after starting and for 4 weeks after every dose increase. This is a labeling instruction for tirzepatide — it is not a rule that applies automatically to every GLP-1 medicine.
  • Progestin-only pills: tirzepatide’s four-week non-oral method or added barrier method precaution applies to oral hormonal contraceptives generally, including progestin-only pills — it is not limited to combined pills. The vomiting and diarrhea algorithms do differ between combined and progestin-only pills, so ask your prescriber or pharmacist what applies to the specific pill you take.
  • Contraceptive patch and vaginal ring: these methods do not rely on stomach absorption and are not expected to be affected by tirzepatide’s delayed gastric emptying. They still carry their own eligibility criteria and adherence requirements, such as changing the patch or ring on schedule.
  • IUDs (hormonal and copper): IUDs do not rely on stomach absorption and are not expected to be affected by tirzepatide’s delayed gastric emptying. An IUD still requires its own placement and follow-up checks.
  • Contraceptive implant and injectable: these methods do not rely on stomach absorption and are not expected to be affected by tirzepatide’s delayed gastric emptying. They still require their own scheduled placement or repeat doses.
  • Emergency contraception: if you need emergency contraception, contact a pharmacist or clinician promptly and tell them about tirzepatide, your regular contraception, any vomiting or diarrhea, and when unprotected sex occurred. The appropriate option and timing need individual assessment.

Vomiting/diarrhea advice depends on your pill and duration of illness. For combined oral pills, CDC advises backup contraception when vomiting or diarrhea continues for 48 hours or longer, continuing until 7 consecutive hormonal pills have been taken after symptoms resolve. Additional instructions depend on the week of the pill pack and recent sex. Contact your pharmacist or prescriber; do not apply this combined-pill rule to a progestin-only pill. The full algorithm is in the CDC U.S. Selected Practice Recommendations for combined hormonal contraceptives.

This vomiting and diarrhea guidance is separate from tirzepatide’s four-week backup precaution. Following one does not replace the other.

Pregnancy: what to plan for

Tell your prescriber if you are pregnant, could become pregnant, are planning pregnancy, or are breastfeeding. Tirzepatide used for weight management should be stopped when pregnancy is recognized. Weight loss offers no benefit during pregnancy, and tirzepatide may harm the fetus. Contact your prescriber promptly if pregnancy occurs or is suspected.

Stopping before a planned pregnancy is a separate question from the pill interaction, and the answers differ by medicine. The US semaglutide label advises stopping at least 2 months before planned pregnancy. The US Zepbound label does not specify a stopping interval; UK guidance advises at least 1 month for tirzepatide. Plan this with your prescriber rather than assuming one interval covers every GLP-1 medicine.

Questions to ask your prescriber

Before starting GLP-1 treatment, have a direct conversation about contraception. Useful questions: which category does my current method fall into, and is it affected by delayed gastric emptying? If I use combined pills, should I switch to a non-oral method or add a barrier method for the first 4 weeks and after each dose increase? What should I do if I have vomiting or diarrhea lasting more than 48 hours? And what is my pregnancy plan — including any stopping interval my prescriber recommends?

The bottom line

The interaction between tirzepatide and oral contraceptives is manageable — not a reason to avoid treatment if it is otherwise appropriate for you. Know which category your contraceptive falls into, follow the specific instruction for the medicine you are prescribed rather than a general rule, and have an explicit conversation before starting. Do not assume your prescriber will raise the topic — bring it up yourself. If pregnancy occurs or is suspected while on treatment, contact your prescriber promptly.

Frequently asked questions

Tirzepatide has a specific four-week backup/non-oral contraception instruction. The current Wegovy label reports no clinically significant change in exposure to ethinyl estradiol or levonorgestrel with semaglutide. Do not automatically apply tirzepatide’s interaction rule to semaglutide. Vomiting or diarrhea still requires advice specific to the contraceptive being used.

An IUD — hormonal or copper — does not rely on stomach absorption and is not expected to be affected by tirzepatide’s delayed gastric emptying. That is separate from the IUD’s own requirements: it still needs correct placement, checking, and replacement on schedule.

Contact your prescriber promptly and take a pregnancy test. Tirzepatide used for weight management should be stopped when pregnancy is recognized. Do not continue treatment during pregnancy, and discuss the situation with your prescriber and your obstetric clinician.

It depends on the medicine, and the labels differ. The US semaglutide label advises stopping at least 2 months before a planned pregnancy. The US Zepbound label does not specify a stopping interval; UK guidance advises stopping tirzepatide at least 1 month beforehand. Your prescriber should individualize the plan with you.

Sources

This guide is published by Surfbound Health (Organization). It is educational content, not medical advice, and it does not replace an individual evaluation by a licensed provider.

Sources

Want more evidence-based health research from Surfbound?

Add Surfbound as a Preferred Source on Google